Cargando…

Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility

INTRODUCTION: Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines classify chronic kidney disease (CKD) risk or prognosis using estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR). We assessed patient characteristics and outcomes according to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	James, Glen, Garcia Sanchez, Juan Jose, Carrero, Juan Jesus, Kumar, Supriya, Pecoits-Filho, Roberto, Heerspink, Hiddo J.L., Nolan, Stephen, Lam, Carolyn S.P., Chen, Hungta, Kanda, Eiichiro, Kashihara, Naoki, Arnold, Matthew, Kosiborod, Mikhail N., Lainscak, Mitja, Pollock, Carol, Wheeler, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458998/ https://www.ncbi.nlm.nih.gov/pubmed/36090504 http://dx.doi.org/10.1016/j.ekir.2022.05.033

Ejemplares similares

Methods and rationale of the DISCOVER CKD global observational study
por: Pecoits-Filho, Roberto, et al.
Publicado: (2021)

Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort
por: Pollock, Carol, et al.
Publicado: (2022)

Cost of End-of-Life Inpatient Encounters in Patients with Chronic Kidney Disease in the United States: A Report from the DISCOVER CKD Retrospective Cohort
por: Pollock, Carol, et al.
Publicado: (2022)

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
por: McEwan, Phil, et al.
Publicado: (2022)

Nephrologists’ Perspectives on Gender Disparities in CKD and Dialysis
por: Tong, Allison, et al.
Publicado: (2021)

The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial
por: Willigers, Bartholomeus J. A., et al.
Publicado: (2023)

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2021)

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD
por: Heerspink, Hiddo J.L., et al.
Publicado: (2021)

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study
por: Beernink, Jelle M., et al.
Publicado: (2023)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Optimizing Diet to Slow CKD Progression
por: Molina, Pablo, et al.
Publicado: (2021)

Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
por: Eckardt, Kai-Uwe, et al.
Publicado: (2018)

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists
por: Provenzano, Michele, et al.
Publicado: (2021)

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA‐CKD Trial
por: Chertow, Glenn M., et al.
Publicado: (2023)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Identifying progressive CKD from healthy population using Bayesian network and artificial intelligence: A worksite-based cohort study
por: Kanda, Eiichiro, et al.
Publicado: (2019)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases
por: Damron, Kelli Collins, et al.
Publicado: (2022)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

10. Cardiovascular Risk in Chronic Kidney Disease
por: Lainščak, Mitja
Publicado: (2009)

Machine-learning-based Web system for the prediction of chronic kidney disease progression and mortality
por: Kanda, Eiichiro, et al.
Publicado: (2023)

Machine learning models for prediction of HF and CKD development in early-stage type 2 diabetes patients
por: Kanda, Eiichiro, et al.
Publicado: (2022)

Investigating the global prevalence and consequences of undiagnosed stage 3 chronic kidney disease: methods and rationale for the REVEAL-CKD study
por: Kushner, Pamela, et al.
Publicado: (2021)

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan
por: Kashihara, Naoki, et al.
Publicado: (2019)

Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan
por: Kanda, Eiichiro, et al.
Publicado: (2020)

Cardiovascular and Renal Outcomes Associated With Hyperkalemia in Chronic Kidney Disease: A Hospital-Based Cohort Study
por: Kohsaka, Shun, et al.
Publicado: (2021)

eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database
por: Itano, Seiji, et al.
Publicado: (2023)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

ACT‐ONE ‐ ACTION at last on cancer cachexia by adapting a novel action beta‐blocker
por: Lainscak, Mitja, et al.
Publicado: (2016)

Embracing secondary mitral regurgitation with Carillon: past, present, and future
por: Lainscak, Mitja, et al.
Publicado: (2020)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives
por: Martono, Doti P., et al.
Publicado: (2019)

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
por: Tuttle, Katherine R., et al.
Publicado: (2021)

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker
por: Pontillo, Claudia, et al.
Publicado: (2017)

The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure
por: BJORNSTAD, PETTER, et al.
Publicado: (2021)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges
por: Lainscak, Mitja, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_52m8bre4dp0mmitcg1kik46b21